AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B May 3, 2024
AAVantgarde Presents Positive Preclinical Data in Large Animal Models from its Stargardt Disease Program in an Oral Presentation at the ASGCT 2024 Annual Meeting April 23, 2024
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic June 6, 2023
